Royal Bank Of Canada Biovie Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $1,646 - $5,872	-3,107 Reduced 27.74%	8,093 $4,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $12,913 - $55,465	10,585 Added 1721.14%	11,200 $14,000
Q3 2023 Nov 14, 2023	SELL	$2.75 - $5.17 $34,157 - $64,216	-12,421 Reduced 95.28%	615 $2,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $51,272 - $103,923	12,536 Added 2507.2%	13,036 $56,000
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $1,571 - $17,094	407 Added 437.63%	500 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.38 - $25.6 $82 - $1,536	60 Added 181.82%	93 $0
Q2 2022 Aug 15, 2022	BUY	$1.44 - $5.04 $47 - $166	33 New	33 $0
Q1 2022 May 16, 2022	SELL	$2.74 - $5.65 $64,390 - $132,775	-23,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $103,635 - $164,265	23,500 New	23,500 $106,000

4.73M

17.2K

27K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.